Lexicon Pharmaceuticals Overview

  • Founded
  • 1995

Founded
  • Status
  • Public

  • Employees
  • 87

Employees
  • Stock Symbol
  • LXRX

Stock Symbol
  • Investments
  • 3

  • Share Price
  • $2.24

  • (As of Tuesday Closing)

Lexicon Pharmaceuticals General Information

Description

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Contact Information

Formerly Known As
Lexicon Genetics
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 2445 Technology Forest Boulevard
  • 11th Floor
  • The Woodlands, TX 77381-1160
  • United States
+1 (281) 000-0000

Lexicon Pharmaceuticals Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lexicon Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.24 $2.17 $1.31 - $3.48 $410M 189M 378K -$0.62

Lexicon Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 416,396 479,932 393,345 389,850
Revenue 125 298 23,995 322,073
EBITDA (95,376) (86,798) (43,863) 145,099
Net Income (97,061) (87,758) (58,574) 130,133
Total Assets 191,685 136,909 203,788 417,715
Total Debt 30,628 2,279 12,810 245,736
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lexicon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lexicon Pharmaceuticals‘s full profile, request access.

Request a free trial

Lexicon Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercializ
Pharmaceuticals
The Woodlands, TX
87 As of 2021
00000
000000000 00000

000000

llamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in
0000000000000
Newark, CA
00 As of 0000
00000
00000000 00000

000000

uat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor
0000000000000
Boston, MA
000 As of 0000
00000
0000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lexicon Pharmaceuticals Competitors (104)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CymaBay Therapeutics Formerly VC-backed Newark, CA 00 00000 00000000 00000
0000000 Formerly PE-Backed Boston, MA 000 00000 000000&0 00000
000000 00000000000 Formerly VC-backed San Diego, CA 000 00000 000000&0
00000 000000000000 Formerly VC-backed Foster City, CA 000 00000 000000000 00000
00000 000000000000 Formerly VC-backed San Francisco, CA 00 00000 000000&0 00000
You’re viewing 5 of 104 competitors. Get the full list »

Lexicon Pharmaceuticals Patents

Lexicon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220370485-A1 Compounds and methods for treating or preventing cardiovascular diseases and conditions Pending 14-Jan-2021 0000000000
AU-2021259419-A1 Aak1 inhibitors for use in treating viral infections Pending 21-Apr-2020 0000000000
CA-3175970-A1 Aak1 inhibitors for use in treating viral infections Pending 21-Apr-2020 0000000000
US-20220054464-A1 Compounds and methods for treating viral infections Pending 21-Apr-2020 0000000000
AU-2021258128-A1 4-(3-(pyridin-3-yl)pyrazolo(1,5-a)pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections Pending 21-Apr-2020 A61K31/519
To view Lexicon Pharmaceuticals’s complete patent history, request access »

Lexicon Pharmaceuticals Executive Team (17)

Name Title Board Seat Contact Info
Lonnel Coats Chief Executive Officer & Board Member
Jeffrey Wade JD Chief Financial Officer, Finance & President
Kristen Alexander Chief Accounting Officer, Accounting & Vice President
Kiernan Seth Ph.D Executive & Vice President
Alan Main Ph.D Executive Vice President
You’re viewing 5 of 17 executive team members. Get the full list »

Lexicon Pharmaceuticals Board Members (9)

Name Representing Role Since
0000 0000 00 Self Board Member 000 0000
00000000000 000000 The Invus Group Board Member 000 0000
00000 000000000 Self Board Member 000 0000
000000 00000 Self Board Member 000 0000
000000 00000 Lexicon Pharmaceuticals Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Lexicon Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lexicon Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lexicon Pharmaceuticals‘s full profile, request access.

Request a free trial

Lexicon Pharmaceuticals Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 02-Aug-2010 0000000000 0000 Pharmaceuticals 000000 00
00000000 0000 01-Jun-2007 00000 0000 Pharmaceuticals 000000 00
Coelacanth Chemical 12-Jul-2001 Merger/Acquisition 0000 Pharmaceuticals 000000 00
To view Lexicon Pharmaceuticals’s complete investments and acquisitions history, request access »

Lexicon Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 25, 2022

25.38 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 462

Rank

00.00

Percentile

To view Lexicon Pharmaceuticals’s complete esg history, request access »